• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis.

作者信息

Carcao Manuel, Shapiro Amy, Hwang Nina, Pipe Steven, Ahuja Sanjay, Lieuw Ken, Staber Janice M, Belletrutti Mark, Sun Haowei Linda, Ding Hilda, Wang Michael, Price Victoria, Steele MacGregor, Tsao Elisa, Feng Jing, Al-Khateeb Zahra, Dumont Jennifer, Jain Nisha

机构信息

The Hospital for Sick Children, Toronto, ON, Canada.

Indiana Hemophilia & Thrombosis Center, Inc, Indianapolis, IN, USA.

出版信息

Haemophilia. 2021 Jan;27(1):19-25. doi: 10.1111/hae.14192. Epub 2020 Nov 18.

DOI:10.1111/hae.14192
PMID:33210397
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8243250/
Abstract
摘要

相似文献

1
Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis.使用重组因子VIII Fc融合蛋白对免疫耐受诱导失败高风险的重度A型血友病伴抑制剂患者进行免疫耐受诱导的真实世界数据：一项随访回顾性分析。
Haemophilia. 2021 Jan;27(1):19-25. doi: 10.1111/hae.14192. Epub 2020 Nov 18.
2
Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.用于诱导有抑制剂的重度 A 型血友病患者免疫耐受的重组凝血因子 VIII Fc 融合蛋白：一项回顾性分析。
Haemophilia. 2018 Mar;24(2):245-252. doi: 10.1111/hae.13413. Epub 2018 Feb 13.
3
Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.在使用重组因子VIII-Fc融合蛋白进行免疫耐受诱导期间因子VIII抑制物滴度的降低
Pediatr Blood Cancer. 2016 May;63(5):922-4. doi: 10.1002/pbc.25874. Epub 2016 Jan 6.
4
Immune tolerance induction using Fc-fusion-protein recombinant factor IX in severe haemophilia B.使用Fc融合蛋白重组因子IX诱导严重B型血友病的免疫耐受
Haemophilia. 2021 Nov;27(6):e776-e779. doi: 10.1111/hae.14424. Epub 2021 Oct 2.
5
First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.在一项观察性免疫耐受诱导研究中，关于高危血友病A抑制物患者使用单一凝血因子VIII/血管性血友病因子浓缩物的免疫耐受的首份前瞻性报告。
Haemophilia. 2016 Jan;22(1):87-95. doi: 10.1111/hae.12774. Epub 2015 Jul 23.
6
Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.A型血友病和 B 型血友病患者中重组因子 VIII Fc 和重组因子 IX Fc 的临床应用。
Haemophilia. 2018 May;24(3):414-419. doi: 10.1111/hae.13432. Epub 2018 Feb 5.
7
Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.在澳大利亚患有高滴度抑制物的儿童重度甲型血友病患者中，使用含或不含免疫抑制的凝血因子 VIII/血管性血友病因子浓缩物（BIOSTATE）诱导免疫耐受：一项多中心回顾性研究。
Thromb Res. 2014 Nov;134(5):1046-51. doi: 10.1016/j.thromres.2014.09.010. Epub 2014 Sep 21.
8
Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.Fc 融合技术在重组凝血因子 VIII 替代治疗中的新获益。
Haemophilia. 2020 Nov;26(6):958-965. doi: 10.1111/hae.14123. Epub 2020 Sep 3.
9
Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study.免疫耐受诱导在血友病 A 患者抑制剂的治疗用重组因子 VIII:回顾性非干预性研究。
Haemophilia. 2013 May;19(3):449-55. doi: 10.1111/hae.12102. Epub 2013 Mar 19.
10
Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution.对重组凝血因子 VIII 高反应性抑制物的甲型血友病患者免疫耐受诱导：单机构经验
Haemophilia. 2001 Jan;7(1):33-8. doi: 10.1046/j.1365-2516.2001.00461.x.

引用本文的文献

1
Immune Tolerance Induction With a Recombinant Factor VIII Fc in Haemophilia A: Data From a Chart Review Study.重组凝血因子VIII Fc诱导甲型血友病免疫耐受：一项病历回顾研究的数据
Eur J Haematol. 2025 Aug;115(2):134-141. doi: 10.1111/ejh.14427. Epub 2025 Apr 27.
2
Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16 NK cell activation.重组凝血因子VIII Fc融合蛋白的凝血因子VIII部分影响Fc效应功能和CD16自然杀伤细胞活化。
Front Immunol. 2024 Apr 9;15:1341013. doi: 10.3389/fimmu.2024.1341013. eCollection 2024.
3
Considerations for shared decision management in previously untreated patients with hemophilia A or B.对既往未经治疗的甲型或乙型血友病患者进行共同决策管理的考量
Ther Adv Hematol. 2023 Apr 17;14:20406207231165857. doi: 10.1177/20406207231165857. eCollection 2023.
4
Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study.用于首次免疫耐受诱导的重组因子 VIII Fc 融合蛋白：verITI-8 研究的最终结果。
Blood. 2023 Apr 20;141(16):1982-1989. doi: 10.1182/blood.2022017780.
5
Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study.在观察性免疫耐受诱导（ObsITI）研究中，对100例患者使用pdFVIII/VWF浓缩物（奥曲肽）进行免疫耐受诱导（ITI）。
TH Open. 2022 May 26;6(2):e124-e134. doi: 10.1055/s-0042-1748756. eCollection 2022 Apr.
6
Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.在具有高抑制剂滴度和免疫耐受诱导治疗成功不良预后因素的阿拉伯裔重度血友病 A 儿童中进行低剂量免疫耐受诱导治疗。
Haemophilia. 2022 Jan;28(1):65-72. doi: 10.1111/hae.14456. Epub 2021 Nov 19.
7
Efmoroctocog Alfa: A Review in Haemophilia A.依非洛欧特奥卡帕：血友病 A 治疗药物。
Drugs. 2021 Nov;81(17):2035-2046. doi: 10.1007/s40265-021-01615-w. Epub 2021 Nov 7.

本文引用的文献

1
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.随着emicizumab 的出现，血友病 A 免疫耐受诱导的面貌正在发生变化。
Haemophilia. 2019 Jul;25(4):676-684. doi: 10.1111/hae.13762. Epub 2019 Apr 29.
2
Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.用于诱导有抑制剂的重度 A 型血友病患者免疫耐受的重组凝血因子 VIII Fc 融合蛋白：一项回顾性分析。
Haemophilia. 2018 Mar;24(2):245-252. doi: 10.1111/hae.13413. Epub 2018 Feb 13.
3
Extended half-life factor VIII for immune tolerance induction in haemophilia.用于血友病免疫耐受诱导的延长半衰期因子VIII。
Haemophilia. 2016 Nov;22(6):e552-e554. doi: 10.1111/hae.13064. Epub 2016 Sep 19.
4
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.重组因子VIII Fc（rFVIIIFc）融合蛋白可降低免疫原性并诱导甲型血友病小鼠产生耐受性。
Cell Immunol. 2016 Mar;301:30-9. doi: 10.1016/j.cellimm.2015.12.008. Epub 2015 Dec 29.
5
Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment.VIII 因子抗体抑制剂：免疫耐受诱导与预防和按需旁路治疗的成本分析。
Haemophilia. 2015 May;21(3):310-319. doi: 10.1111/hae.12621. Epub 2015 Feb 16.
6
Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres.在诊断出抑制剂时，无论效价如何，立即进行免疫耐受诱导可能会增加伴抑制剂的血友病 A 患者的总体成功率：两个美国中心的经验。
Haemophilia. 2015 May;21(3):365-373. doi: 10.1111/hae.12608. Epub 2015 Jan 11.
7
Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.儿童和成人的初级和挽救性免疫耐受诱导：一项含有 VWF 的血浆源性 FVIII 浓缩物的多中心国际研究。
Haemophilia. 2014 Jan;20(1):83-91. doi: 10.1111/hae.12263. Epub 2013 Nov 19.
8
The principal results of the International Immune Tolerance Study: a randomized dose comparison.国际免疫耐受研究的主要结果：一项随机剂量比较。
Blood. 2012 Feb 9;119(6):1335-44. doi: 10.1182/blood-2011-08-369132. Epub 2011 Nov 18.